Literature DB >> 15278919

Comparison of two particulate hexavalent chromium compounds: Barium chromate is more genotoxic than lead chromate in human lung cells.

Sandra S Wise1, Julie H C Schuler, Amie L Holmes, Spiros P Katsifis, Michael E Ketterer, Wendy J Hartsock, Tongzhang Zheng, John Pierce Wise.   

Abstract

Particulate hexavalent chromium [Cr(VI)] compounds are well-established human lung carcinogens. However, their carcinogenic mechanisms are poorly understood as most investigators have used soluble Cr(VI) compounds. Recent work from our laboratory has found that barium chromate (BC) is also cytotoxic and clastogenic. To understand how BC relates to existing data on other particulate Cr(VI) compounds, we compared its cytotoxicity and clastogenicity with lead chromate (LC), which has been used as a prototypical particulate Cr(VI) compound, in WTHBF-6 cells, a near-normal human lung cell line. We found that BC is a more potent cytotoxicant, inducing 67%, 12%, 3%, and 0% relative survival at concentrations of 0.1, 0.5, 1, and 5 microg/cm2, respectively, while LC induced 90%, 71%, 43%, and 15% survival at these same concentrations. We found that BC was also more clastogenic, damaging 22% and 49% of metaphase cells at 0.1 and 0.5 microg/cm2, and causing complete cell cycle arrest at 1 and 5 microg/cm2. By contrast, 0.1, 0.5, and 1.0 microg/cm2 LC damaged 10%, 27%, and 37% of metaphase cells, respectively, and complete cell cycle arrest was not observed until a concentration of 5 microg/cm2 was reached. We found that BC and LC both partially dissolved in complete medium in the presence of cells, producing similar extracellular concentrations. Both compounds were also comparable with respect to particle uptake and the amount of intracellular Cr ions. Considering previous reports showing that lead ions were inactive and that sodium chromate and LC have similar clastogenic potencies, these data suggest that BC genotoxicity may not be solely mediated by Cr ions, but also involve some clastogenic activity of barium ions. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278919     DOI: 10.1002/em.20044

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.216


  6 in total

Review 1.  Chromium genotoxicity: A double-edged sword.

Authors:  Kristen P Nickens; Steven R Patierno; Susan Ceryak
Journal:  Chem Biol Interact       Date:  2010-04-27       Impact factor: 5.192

2.  Comparative genotoxicity and cytotoxicity of four hexavalent chromium compounds in human bronchial cells.

Authors:  Sandra S Wise; Amie L Holmes; Qin Qin; Hong Xie; Spiros P Katsifis; W Douglas Thompson; John Pierce Wise
Journal:  Chem Res Toxicol       Date:  2010-02-15       Impact factor: 3.739

3.  Reductive activation of hexavalent chromium by human lung epithelial cells: generation of Cr(V) and Cr(V)-thiol species.

Authors:  Griselda R Borthiry; William E Antholine; Judith M Myers; Charles R Myers
Journal:  J Inorg Biochem       Date:  2008-01-08       Impact factor: 4.155

4.  Zinc chromate induces chromosome instability and DNA double strand breaks in human lung cells.

Authors:  Hong Xie; Amie L Holmes; Jamie L Young; Qin Qin; Kellie Joyce; Stephen C Pelsue; Cheng Peng; Sandra S Wise; Antony S Jeevarajan; William T Wallace; Dianne Hammond; John Pierce Wise
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-05       Impact factor: 4.219

5.  Chronic exposure to zinc chromate induces centrosome amplification and spindle assembly checkpoint bypass in human lung fibroblasts.

Authors:  Amie L Holmes; Sandra S Wise; Stephen C Pelsue; AbouEl-Makarim Aboueissa; Wilma Lingle; Jeffery Salisbury; Jamie Gallagher; John Pierce Wise
Journal:  Chem Res Toxicol       Date:  2010-02-15       Impact factor: 3.739

Review 6.  Cytogenomics of hexavalent chromium (Cr 6+) exposed cells: a comprehensive review.

Authors:  Akanksha Nigam; Shivam Priya; Preeti Bajpai; Sushil Kumar
Journal:  Indian J Med Res       Date:  2014-03       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.